Match Document Document Title
US20130039912 ROBO1-FC FUSION PROTEIN AND USE THEREOF FOR TREATING TUMOURS  
The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also...
US20150139993 HEMOJUVELIN FUSION PROTEINS AND USES THEREOF  
The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also...
US20120164140 HEMOJUVELIN FUSION PROTEINS AND USES THEREOF  
The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also...
US20150232547 TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS  
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an...
US20140056891 TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS  
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an...
US20120128672 TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS  
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an...
US20130177560 METHODS OF TREATMENT USING RAGE FUSION PROTEINS  
The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatioπ endproducts receptor (RAGE).
US20140143897 EPHA4 IS A DISEASE MODIFIER IN MOTOR NEURON DISEASE  
The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve...
US20150210749 METHODS OF TREATMENT USING FUSION PROTEINS  
The invention relates to method of treatment using fusion proteins. The fusion proteins may be RAGE fusion proteins produce by methods for controlling the glycosylation of the fusion protein. The...
US20130295094 USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS  
The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention...
US20130129727 METHODS AND SYSTEMS FOR INCREASING PROTEIN STABILITY  
Methods and systems for increasing stability of a target polypeptide in a serum are described. The methods and systems utilize a fusion protein comprising a single-domain antibody against a serum...
US20110158993 Train-R: A Cysteine Rich Member of the TNF-Receptor Family  
Novel receptor in the TNF family: TRAIN-receptor.
US20130273049 ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA  
The present invention relates to the use a Robo1-Fc recombinant protein for treating cancer, in particular hepatocarcinoma.
US20140186351 STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc  
The present invention relates to stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc comprising different buffer systems and stabilizers. In particular, it could be...
US20140120091 FUSION PROTEINS FOR THERAPY OF AUTOIMMUNE AND CARDIOVASCULAR DISEASE  
The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease.
US20150158923 Follistatin Fusion Proteins and Uses Thereof  
In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain...
US20140010849 PEANUT ALLERGY TREATMENT  
The present invention provides compositions, systems, and methods for preventing and treating allergic reactions to peanut exposure. In certain embodiments, the present invention employs fusion...
US20120082668 SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS  
Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and...
US20110318345 NASAL DELIVERY  
substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of...
US20130136739 METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS  
Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a...
US20150239953 METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS  
Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
US20140220013 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES  
Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
US20140170064 METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING  
Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic...
US20130078302 Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases  
Compositions and methods useful for the inhibition of cancer metastasis are disclosed.
US20140140995 COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS  
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion...
US20130108628 Method for treating cancer pain and/or rescuing analgesic effect of morphine treatment of cancer pain  
The present invention provides a method for treating cancer pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for...
US20110243943 TREATMENT USING RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES  
Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion...
US20110129468 PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION  
The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance...
US20150098942 CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS  
OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by...
US20150030593 COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE  
The disclosure relates to penetration-enhanced targeted proteins and their uses for therapeutics delivery.
US20140363431 METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS  
The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
US20150017164 COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE  
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS...
US20130216541 STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF  
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for...
US20130243768 MULTIMERIC PROTEINS AND METHODS OF MAKING AND USING SAME  
The invention provides multimerization polypeptides capable of conferring formation of multimers when the multimerization polypeptide is linked to a molecule, such as a heterologous polypeptide...
US20150033410 METHODS AND COMPOSITIONS FOR EMERGENCY POST-INFECTION TREATMENT OF ANTHRAX  
Compositions effective for treating or preventing an anthrax infection in a subject in need thereof and recombinant proteins included in the compositions are provided. Methods for producing...
US20120121590 METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN)  
The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide...
US20140178377 METHODS AND COMPOSITIONS FOR TREATMENT OF MYOTONIC DYSTROPHY  
In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy.
US20150010555 COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE  
Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or...
US20130084291 COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE  
Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or...
US20110171218 COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE  
Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or...
US20140248270 METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS  
A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder,...
US20150160230 METHODS OF PREDICTING AND DECREASING THE RISK OF PRE-TERM BIRTH  
Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for...
US20150086616 METHOD FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE  
Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer's disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen,...
US20130336970 Compositions and Methods for Treating and Diagnosing Cancer  
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in...
US20110243942 RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES  
Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion...
US20120052066 MARKERS AND METHODS FOR ASSESSING AND TREATING LUPUS PATIENTS SUSCEPTIBLE TO PHOTOPROVOCATION  
A method for predicting or detecting susceptibility to lupus of an individual subjected to photoprovocation obtains biological samples from the individual before and after exposure to...
US20110268736 METHOD FOR TREATING CONGENITAL MYOPATHY  
The invention relates to methods and compositions for therapy for congenital myopathies.
US20140193409 FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS  
The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is...
US20140170141 POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION  
This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune...
US20130216540 MODULATION OF THE INNATE IMMUNE SYSTEM THROUGH THE TREM-LIKE TRANSCRIPT 2 PROTEIN  
TREM-like transcript 2 (TLT2), is expressed on neutrophils, macrophages, and B lymphocytes. Expression of TLT2 is up-regulated on neutrophils and macrophages in response to inflammatory stimuli in...